What is HC Wainwright’s Forecast for RNA Q3 Earnings?

Posted by Brenda Bartman on Aug 12th, 2026

Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) – Analysts at HC Wainwright issued their Q3 2026 EPS estimates for Avidity Biosciences in a research note issued on Thursday, August 6th. HC Wainwright analyst M. Kapoor expects that the biotechnology company will post earnings per share of ($2.31) for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Avidity Biosciences’ current full-year earnings is ($5.74) per share. HC Wainwright also issued estimates for Avidity Biosciences’ Q4 2026 earnings at ($2.42) EPS, FY2026 earnings at ($7.89) EPS, Q1 2027 earnings at ($2.63) EPS, Q2 2027 earnings at ($2.67) EPS, Q3 2027 earnings at ($2.74) EPS, Q4 2027 earnings at ($2.24) EPS and FY2027 earnings at ($10.29) EPS.

Several other research analysts have also issued reports on RNA. Wall Street Zen upgraded Avidity Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, May 30th. Cantor Fitzgerald began coverage on Avidity Biosciences in a report on Thursday, June 18th. They set an “overweight” rating and a $25.00 price objective for the company. Weiss Ratings raised Avidity Biosciences from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. Leerink Partners started coverage on Avidity Biosciences in a research report on Friday, May 15th. They set an “outperform” rating on the stock. Finally, Zacks Research upgraded Avidity Biosciences to a “hold” rating in a report on Friday, June 19th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Avidity Biosciences has an average rating of “Hold” and an average target price of $63.85.

View Our Latest Research Report on RNA

Avidity Biosciences Price Performance

Shares of Avidity Biosciences stock opened at $12.27 on Monday. Avidity Biosciences has a one year low of $11.13 and a one year high of $16.77. The firm has a market capitalization of $209.94 million and a price-to-earnings ratio of -12.65. The business has a 50-day simple moving average of $12.35 and a 200 day simple moving average of $23.98.

Avidity Biosciences (NASDAQ:RNA – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.08. The company had revenue of $19.64 million for the quarter, compared to analyst estimates of $2.00 million.

Hedge Funds Weigh In On Avidity Biosciences

Several large investors have recently added to or reduced their stakes in RNA. EFG International AG bought a new stake in Avidity Biosciences during the 4th quarter worth approximately $33,000. Smartleaf Asset Management LLC lifted its holdings in shares of Avidity Biosciences by 426.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 490 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 397 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Avidity Biosciences during the fourth quarter valued at approximately $34,000. Clearstead Advisors LLC purchased a new position in shares of Avidity Biosciences during the fourth quarter valued at approximately $72,000. Finally, Longfellow Investment Management Co. LLC purchased a new position in shares of Avidity Biosciences during the fourth quarter valued at approximately $77,000.

About Avidity Biosciences

(Get Free Report)

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.